Chad Messer
Stock Analyst at Lake Street
(2.00)
# 3,253
Out of 4,396 analysts
527
Total ratings
37.2%
Success rate
0.2%
Average return
Main Sectors:
Stocks Rated by Chad Messer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OSTX OS Therapies | Maintained: Buy | $13 | $1.74 | +647.13% | 18 | Jun 3, 2026 | |
| ONCY Oncolytics Biotech | Maintained: Buy | $5 | $0.81 | +517.28% | 18 | Jun 1, 2026 | |
| MNPR Monopar Therapeutics | Maintained: Buy | $103 | $60.11 | +71.35% | 6 | Jun 1, 2026 | |
| IMNM Immunome | Maintained: Buy | $30 | $18.39 | +63.13% | 9 | Jun 1, 2026 | |
| COYA Coya Therapeutics | Maintained: Buy | $17 | $4.48 | +279.46% | 14 | May 22, 2026 | |
| CGEN Compugen | Reiterated: Buy | $6 | $2.02 | +197.77% | 2 | May 19, 2026 | |
| PSTV Plus Therapeutics | Maintained: Buy | $50 | $5.50 | +809.09% | 5 | May 19, 2026 | |
| LTRN Lantern Pharma | Maintained: Buy | $25 | $3.81 | +556.17% | 13 | May 18, 2026 | |
| BOLT Bolt Biotherapeutics | Maintained: Buy | $75 | $4.62 | +1,523.38% | 6 | May 13, 2026 | |
| GNLX Genelux | Maintained: Buy | $16 | $2.98 | +437.82% | 5 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.59 | - | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $7 | $6.85 | n/a | 18 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | kr 340.00 → kr 380.00 | $178.10 | n/a | 13 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $3 | $1.12 | n/a | 17 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 | $8.65 | n/a | 7 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $49 | $4.27 | n/a | 5 | Aug 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.000001 | n/a | 11 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $50 | $92.59 | n/a | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $48 | $68.45 | n/a | 31 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $2.33 | n/a | 13 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 | $0.92 | n/a | 17 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $12 | $76.44 | n/a | 19 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $21 | $1.46 | n/a | 17 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $36.94 | n/a | 25 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $84 | $74.58 | n/a | 50 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $134 → $114 | $3.14 | n/a | 34 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $6 | $0.0001 | n/a | 17 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $48 | $15.64 | n/a | 6 | Jul 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $33 → $30 | $52.99 | n/a | 22 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 → $83 | $1.59 | n/a | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $166 | $15.89 | n/a | 50 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 | $0.3057 | n/a | 2 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $28.21 | n/a | 21 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.22 | n/a | 3 | Nov 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $27 | $14.29 | n/a | 3 | Apr 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $33 | $5.60 | n/a | 10 | Dec 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $7 | $0.00004 | n/a | 5 | May 7, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $7.68 | n/a | 6 | Mar 6, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $1.24 | n/a | 1 | Jan 5, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $2.38 | n/a | 1 | May 22, 2012 |
OS Therapies
Jun 3, 2026
Maintained: Buy
Price Target: $13
Current: $1.74
Upside: +647.13%
Oncolytics Biotech
Jun 1, 2026
Maintained: Buy
Price Target: $5
Current: $0.81
Upside: +517.28%
Monopar Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $103
Current: $60.11
Upside: +71.35%
Immunome
Jun 1, 2026
Maintained: Buy
Price Target: $30
Current: $18.39
Upside: +63.13%
Coya Therapeutics
May 22, 2026
Maintained: Buy
Price Target: $17
Current: $4.48
Upside: +279.46%
Compugen
May 19, 2026
Reiterated: Buy
Price Target: $6
Current: $2.02
Upside: +197.77%
Plus Therapeutics
May 19, 2026
Maintained: Buy
Price Target: $50
Current: $5.50
Upside: +809.09%
Lantern Pharma
May 18, 2026
Maintained: Buy
Price Target: $25
Current: $3.81
Upside: +556.17%
Bolt Biotherapeutics
May 13, 2026
Maintained: Buy
Price Target: $75
Current: $4.62
Upside: +1,523.38%
Genelux
May 8, 2026
Maintained: Buy
Price Target: $16
Current: $2.98
Upside: +437.82%
Apr 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.59
Upside: -
Nov 1, 2021
Maintained: Buy
Price Target: $6 → $7
Current: $6.85
Upside: n/a
Sep 1, 2021
Reiterated: Buy
Price Target: kr 340.00 → kr 380.00
Current: $178.10
Upside: n/a
Aug 17, 2021
Rated: Buy
Price Target: $3
Current: $1.12
Upside: n/a
Aug 13, 2021
Maintained: Buy
Price Target: $29
Current: $8.65
Upside: n/a
Aug 12, 2021
Maintained: Buy
Price Target: $49
Current: $4.27
Upside: n/a
Aug 10, 2021
Maintained: Buy
Price Target: $5
Current: $0.000001
Upside: n/a
Aug 10, 2021
Rated: Buy
Price Target: $50
Current: $92.59
Upside: n/a
Aug 6, 2021
Rated: Buy
Price Target: $48
Current: $68.45
Upside: n/a
Aug 6, 2021
Rated: Buy
Price Target: $30
Current: $2.33
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $10
Current: $0.92
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $12
Current: $76.44
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $21
Current: $1.46
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $36.94
Upside: n/a
Aug 4, 2021
Rated: Buy
Price Target: $84
Current: $74.58
Upside: n/a
Aug 3, 2021
Rated: Buy
Price Target: $134 → $114
Current: $3.14
Upside: n/a
Jul 29, 2021
Rated: Buy
Price Target: $6
Current: $0.0001
Upside: n/a
Jul 15, 2021
Rated: Buy
Price Target: $48
Current: $15.64
Upside: n/a
Jun 28, 2021
Maintained: Buy
Price Target: $33 → $30
Current: $52.99
Upside: n/a
Jun 7, 2021
Reiterated: Buy
Price Target: $75 → $83
Current: $1.59
Upside: n/a
May 18, 2021
Reiterated: Buy
Price Target: $166
Current: $15.89
Upside: n/a
May 14, 2021
Rated: Buy
Price Target: $10
Current: $0.3057
Upside: n/a
May 10, 2021
Rated: Hold
Price Target: n/a
Current: $28.21
Upside: n/a
Nov 8, 2019
Rated: Hold
Price Target: n/a
Current: $4.22
Upside: n/a
Apr 12, 2018
Maintained: Buy
Price Target: $30 → $27
Current: $14.29
Upside: n/a
Dec 9, 2016
Reiterated: Buy
Price Target: $6 → $33
Current: $5.60
Upside: n/a
May 7, 2015
Reiterated: Buy
Price Target: $10 → $7
Current: $0.00004
Upside: n/a
Mar 6, 2015
Maintained: Buy
Price Target: $7 → $4
Current: $7.68
Upside: n/a
Jan 5, 2015
Initiated Coverage: Buy
Price Target: $17
Current: $1.24
Upside: n/a
May 22, 2012
Initiated Coverage: Buy
Price Target: $5
Current: $2.38
Upside: n/a